Tranexamic acid (TA) used in a variety of conditions associated with bleeding has been associated with potential thrombotic side effects such as formation of thrombi and pulmonary embolism (PE). We describe a case of a woman with chronic hemoptysis and a history of PE, who recently used TA as a prophylactic measure, which could have resulted in a new episode of PE. Tranexamic acid probably played a contributory role in the development of her second PE.
Tranexamic acid (TA) is one of the two synthetic derivatives of the amino acid lysine, which is about 10 times more potent than aminocaproic acid and is used in a variety of conditions associated with excessive bleeding such as hemoptysis or menorrhagia. 1, 2 The potential thrombotic risk of TA has been a matter of discussion since the introduction of this drug. It may be a result of the inhibition of fibrinolysis and the consequent clot stabilization. 1, 2 According to the Cochrane Database of Systematic Reviews, the antifibrinolytic drugs TA, aminocaproic acid, and aprotinin do not seem to increase the risk of thrombosis if they are used during or after surgery. 3 However, cases have been reported in literature describing pulmonary embolism (PE) and the formation of thrombi in association with TA treatment in patients who did not undergo surgery. 2, 4 We describe a case of a woman with a history of PE who recently used TA for chronic hemoptysis due to bronchiectasis. She did not have hemoptysis when she started with TA but she developed a new episode of PE. Tranexamic acid probably played a contributory role in the development of this second PE.
Case Presentation
A 59-year-old woman with a history of PE and lung resections because of idiopathic bronchiectasis, that is, a resection of the left lower lobe and a segment of the left upper lobe, was admitted to our hospital with unexplained acute chest pain during breathing. There were no known acquired risk factors for venous thromboembolism except a history of previous idiopathic PE before 20 years (inherited thrombophilia was not investigated).
Because of her chronic hemoptysis she had been successfully treated with oral TA, 4000 mg daily, during the previous 6 months (it was her first treatment with TA).
Routine physical examination did not show any abnormalities. She was afebril and her hemodynamic parameters were stable. Her chest pain could not be provocated by palpation and there were no signs of deep venous thrombosis. Arterial blood gas analysis was unremarkable and the chest x-ray also did not show any new abnormalities.
Because of her previous PE and the absence of an alternative diagnosis (Wells score was 4.5, which indicated a high probability of PE), we decided to perform additional imaging. Computed tomography was not performed initially because of a history of allergy to iodine-containing contrast agents. A ventilation-perfusion scintigraphy was performed, which revealed decreased perfusion in the left upper lobe with a normal ventilation pattern and hence interpreted as a high probability for PE ( Figure 1 ). These findings were not previously seen on a ventilation-perfusion scintigraphy taken before 20 years.
The TA was stopped and anticoagulant therapy was started cautiously (high international normalized ratio [INR] values >3 were avoided) because of the history of chronic hemoptysis. Her chest pain ceased within a few days and long-term (strictly speaking lifelong) anticoagulation was required.
Discussion
Tranexamic acid is an hemostatic drug with antifibrinolytic activity and is widely used in a variety of conditions associated with excessive bleeding such as hemoptysis. Its antifibrinolytic activity is based on blockage of plasminogen, preventing the binding of plasminogen to fibrin and the subsequent activation of plasminogen. 1 Fibrinolysis is a natural mechanism of defense against thrombosis and thrombotic events that are reported in patients using TA 2, 4 , therefore, may be the result of inhibition of fibrinolysis and clot stabilization by TA.
The side effects of TA are dose dependent and have been related to long treatment duration and to high doses of this drug. 4 Our patient had used 4000 mg TA daily for 6 months, and she also had a history of PE. She had no other risk factors for venous thromboembolism. Although direct causality has not been established, the significant temporal association and the absence of any other risk factor suggest that TA played a contributory role in the recurrence of PE in this patient. The potential thrombotic risk of TA may be underestimated.
According to the Cochrane Database of Systematic Reviews, antifibrinolytic drugs provide intraoperative reduction in blood loss and reduction in the need for transfusion. These drugs also do not seem to increase the risk of thrombosis if used perioperatively. 3 Sundström et al 5 did try to investigate the risk of thrombosis in women with menorrhagia using the General Practice Research Database and concluded that TA was associated with an increased risk of venous thromboembolism, but this effect was not statistically significant. However, the number of exposed women was too low to reach a definite conclusion. 5 They suggested that even menorrhagia itself might be a prothrombotic condition.
We probably need large comparative trials to assess the real safety and efficacy of the various doses of TA in nonsurgical populations.
In the meantime, we should be cautious when prescribing TA especially in case of patients with a history of PE (active venous thromboembolism is already a well-known contraindication for prescription of TA). 
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